Alx Oncology Holdings Inc (ALXO)

07:51 AM

ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - Yahoo Finance

07:51 AM

Apr 27, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Apr 27, 2025

Apr 26, 2025

ALX Oncology faces Nasdaq delisting over price rule - Investing.com Australia

Apr 26, 2025

Apr 26, 2025

ALX Oncology (ALXO) Stock Dips After Phase 2 Trial Setback - GuruFocus

Apr 26, 2025

Apr 25, 2025

Evorpacept fails to meet trial endpoints in HNSCC - Investing.com

Apr 25, 2025

Apr 25, 2025

ALX Oncology faces Nasdaq delisting over price rule By Investing.com - Investing.com South Africa

Apr 25, 2025

Apr 25, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Tr - GuruFocus

Apr 25, 2025

Apr 25, 2025

Sector Update: Health Care - marketscreener.com

Apr 25, 2025

Apr 25, 2025

Alx Oncology Holdings Inc: Rising -96.84% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 25, 2025

Apr 25, 2025

ALX Oncology (ALXO) Reports Promising Phase 1 Trial Results for Evorpacept in B-Cell Lymphoma | ALXO Stock News - GuruFocus

Apr 25, 2025

Apr 25, 2025

Evorpacept fails to meet trial endpoints in HNSCC By Investing.com - Investing.com South Africa

Apr 25, 2025

Apr 25, 2025

ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity - marketscreener.com

Apr 25, 2025

Apr 25, 2025

ALX Oncology Reports Promising Phase 1 Results for Evorpacept in Combination with Rituximab and Lenalidomide in B-cell Non-Hodgkin Lymphoma at AACR 2025 - Nasdaq

Apr 25, 2025

Apr 25, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewswire

Apr 25, 2025

Apr 25, 2025

Breakthrough: New Lymphoma Treatment Achieves 83% Complete Response Rate, Outperforming Standard Therapy - Stock Titan

Apr 25, 2025

Apr 25, 2025

ALX Oncology stock falls on trial setback (ALXO:NASDAQ) - Seeking Alpha

Apr 25, 2025

Apr 25, 2025

ALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary Endpoints - Nasdaq

Apr 25, 2025

Apr 25, 2025

ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints - marketscreener.com

Apr 25, 2025

Apr 25, 2025

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evalua - GuruFocus

Apr 25, 2025

Apr 25, 2025

ALX Oncology (ALXO) Shares Update After Phase 2 Trials Yield Mixed Results | ALXO Stock News - GuruFocus

Apr 25, 2025

Apr 25, 2025

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials - GlobeNewswire

Apr 25, 2025

Apr 25, 2025

ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer TrialsWhat's Next? - Stock Titan

Apr 25, 2025

Apr 13, 2025

Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World

Apr 13, 2025

Apr 10, 2025

ALXO stock plunges to 52-week low of $0.48 amid market challenges - Investing.com India

Apr 10, 2025

Apr 10, 2025

ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com - Investing.com South Africa

Apr 10, 2025

Apr 07, 2025

ALX Oncology advances new cancer drug into Phase 1 trials By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate - GlobeNewswire

Apr 07, 2025

Apr 07, 2025

ALX Oncology gets FDA nod to begin trial of ALX2004 (ALXO) - Seeking Alpha

Apr 07, 2025

Apr 07, 2025

FDA clears ALX Oncology’s IND for ALX-2004 - BioWorld MedTech

Apr 07, 2025

Apr 07, 2025

Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004 - marketscreener.com

Apr 07, 2025

Apr 07, 2025

ALX Oncology advances new cancer drug into Phase 1 trials - Investing.com

Apr 07, 2025

Apr 07, 2025

Breakthrough Cancer Drug Gets FDA Green Light: ALX2004 Targets Multiple Solid Tumors - Stock Titan

Apr 07, 2025

Apr 02, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Apr 02, 2025

Mar 31, 2025

ALXO stock touches 52-week low at $0.65 amid market challenges - Investing.com Australia

Mar 31, 2025

Mar 21, 2025

Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology - Defense World

Mar 21, 2025

Mar 20, 2025

ALXO stock plunges to 52-week low of $0.73 amid market challenges - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

ALXO stock plunges to 52-week low of $0.73 amid market challenges By Investing.com - Investing.com South Africa

Mar 20, 2025

Mar 20, 2025

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo

Mar 20, 2025

Mar 15, 2025

Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN

Mar 15, 2025

Mar 13, 2025

ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 12, 2025

Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com

Mar 12, 2025

Mar 10, 2025

ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks

Mar 10, 2025

Mar 09, 2025

Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World

Mar 09, 2025

Mar 09, 2025

ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 09, 2025